Evaluation of Postoperative Pain Control and Quality of Recovery in Patients Using Intravenous Patient-Controlled Analgesia with Fentanyl: A Prospective Randomized Study

Hiroe Onaka¹, Masashi Ishikawa¹, Yoshiaki Mizuguchi², Eiji Uchida² and Atsuhiro Sakamoto¹

¹Department of Anesthesiology and Pain Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
²Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan

Aim: Opioids are increasingly used to control postoperative pain via intravenous patient-controlled analgesia, with several advantages. The present study evaluated the effects of intravenous patient-controlled analgesia with different doses of fentanyl on postoperative pain and on the quality of physical/emotional recovery from surgery and anesthesia.

Methods: We retrospectively reviewed data from 288 patients, and evaluated whether intravenous patient-controlled analgesia with fentanyl correlated with the degree of postoperative pain. We then prospectively studied 47 patients who underwent elective laparoscopic cholecystectomy. The patients were randomized into 2 groups (15 or 30 μg/mL of fentanyl), and postoperative pain control was compared using a visual analog scale score. Furthermore, the Japanese 40-item quality of recovery (QoR-40J) score (global and dimensional) and Hospital Anxiety and Depression Scale (HADS) were used to assess the quality of recovery from surgery and anesthesia.

Results: Of 288 patients, 20% complained of intolerable pain and 18% experienced postoperative nausea and vomiting. In the prospective study, the visual analog scale pain score was lower in the Fentanyl 30 group than in the Fentanyl 15 group (p<0.05) on postoperative day 1. Dimensional QoR-40J pain subscales correlated with both the emotional state subscales (postoperative day 1, p<0.05; day 2, p<0.05) and global QoR-40 scores on both postoperative days (day 1, p<0.05; day 2, p<0.05).

Conclusion: The postoperative pain as well as the physical and emotional quality of recovery in the patients who underwent laparoscopic cholecystectomy could be alleviated by sufficient doses of opioids. (J Nippon Med Sch 2016; 83: 158–166)

Key words: 40-item quality of recovery score, fentanyl, laparoscopic surgery, patient-controlled analgesia, postoperative pain

Introduction

Opioids are most frequently used to control postoperative pain. Several routes, including general, epidural, spinal, and local analgesia, have been applied for controlling postoperative pain¹. Opioids administered via intravenous patient-controlled analgesia (IVPCA) have the potential to be used increasingly, with several advantages: IVPCA has fewer side effects, including nerve damage, epidural hematoma, etc.² IVPCA can be administered to patients receiving anticoagulant medication and can achieve pain control equal to those of patient-controlled epidural analgesia. However, no basic guidelines or protocols for preventing side effects have been established, and an optimal method of pain control has not yet been determined.

Advances in anesthetic management and widespread use of minimally invasive surgery, such as laparoscopic cholecystectomy, have reduced morbidity, enhanced recovery, and allowed an earlier resumption of daily activities². However, postoperative analgesia is still required.
Evaluation of Pain and Quality of Recovery

Table 1  Retrospective data about postoperative pain and antiemetics

| Department                 | Total | Intolerable pain | Manageable pain | No pain | Using anti-emetic during surgery | PONV* | Cessation of IVPCA* |
|----------------------------|-------|------------------|-----------------|--------|----------------------------------|-------|---------------------|
| Urology                    | 11    | 1                | 8               | 2      | 2                                | 1     | 0                   |
| Gynecology                 | 71    | 8                | 59              | 4      | 38                               | 18    | 5                   |
| Plastic surgery            | 32    | 6                | 23              | 3      | 12                               | 7     | 2                   |
| Thoracic surgery           | 1     | 0                | 0               | 1      | 0                                | 0     | 0                   |
| Otolaryngology             | 5     | 0                | 4               | 1      | 1                                | 0     | 0                   |
| Gastrointestinal surgery   | 87    | 29               | 54              | 4      | 26                               | 10    | 8                   |
| Cardiovascular surgery     | 18    | 4                | 12              | 2      | 0                                | 4     | 1                   |
| Orthopedics                | 34    | 11               | 23              | 0      | 9                                | 8     | 5                   |
| Emergency center           | 16    | 0                | 16              | 0      | 3                                | 0     | 0                   |
| Endocrine surgery          | 1     | 0                | 1               | 0      | 0                                | 0     | 0                   |
| Breast surgery             | 3     | 0                | 3               | 0      | 2                                | 1     | 0                   |
| Neurosurgery               | 9     | 0                | 7               | 2      | 0                                | 2     | 2                   |
| Total                      | 288   | 59               | 210             | 19     | 94                               | 52    | 23                  |

*PONV, postoperative vomiting and nausea
*IVPCA, intravenous patient-controlled analgesia

in laparoscopic surgery, as postoperative pain could be associated with prolonged hospitalization and increased morbidity.10 It has been reported that the majority of patients receiving only periodic oral NSAID treatment after laparoscopic surgery claimed to experience a moderate-to-high level of pain, and continued to report pain even after 1 week postoperatively, indicating a requirement of opioid administration11. Taking all into consideration, the optimal regimen of the opioid administration for postoperative analgesia remains to be elucidated.

The aim of the present study was 1) to elucidate the optimal dose of the fentanyl IVPCA and 2) to evaluate the association between postoperative pain relief and the patient’s satisfaction.

Materials and Methods

Patients and Study Design
The study protocol was approved by the Institutional Review Board of Nippon Medical School Hospital (Tokyo, Japan).

First, we retrospectively collected and reviewed data of the medical records of patients who received IVPCA (Coopdech Syringejector; Daikeniki Co., Ltd., Sendai, Japan) for postoperative analgesia from January 2012 to June 2012 (Table 1). All patients (n=288) applied IVPCA as follows: fentanyl (15 μg/mL) at a basal rate of 1.0 mL/h and a 1.0 mL bolus dose, with a lockout time of 10 min. This cohort included patients from several departments as follows: urology, gynecology, plastic surgery, thoracic surgery, otolaryngology, gastrointestinal surgery, cardiovascular surgery, orthopedics, emergency center, endocrine surgery, breast surgery, and neurosurgery.

Second, we further attempted to elucidate the optimal opioid doses of IVPCA analgesia in a prospective study. This study was registered at the University Hospital Medical Information Network Clinical Trials Registry (No. 000010661). Written informed consent was obtained from all subjects. We prospectively collected patients who underwent laparoscopic cholecystectomy from June 2013 to March 2015. Patients (n=47) were randomized into two groups (F15 group: fentanyl with 15 μg/mL; F30 group: fentanyl with 30 μg/mL, see below) using sealed envelopes; patients were blinded to their assignments. Operating room pharmacists prepared medication in IVPCA
pumps labeled with the patient’s name. The inclusion criteria for this study were elective laparoscopic cholecystectomy and age 20–79 years. The exclusion criteria were concomitant disease, including Parkinson’s disease; chronic pain requiring opioid treatment; history of allergy to any medication used in the study; severe renal (i.e., serum creatinine >1.6 mg/dL) or liver disease (i.e., liver enzymes >2-fold normal value); pregnancy; poor comprehension of Japanese; or psychiatric/central nervous system disturbances that would preclude completion of the IVPCA and questionnaires. Patients whose surgical procedure was transferred to open surgery and in whom the IVPCA was discontinued because of severe nausea or vomiting that could not be managed with anti-emetics were also excluded.

We set the primary endpoint as “pain control”, and the secondary endpoint as “quality of recovery after anesthesia and surgery”. To evaluate the primary endpoint, a visual analog scale (VAS) was scored from 0 to 100 mm: 0, no pain; 100, the worst pain imaginable. Both VAS at rest and VAS with movement were scored. The incidence of nausea and vomiting were also recorded at the end of surgery and on postoperative days 1 and 2. In addition, dizziness, headache, and the patient’s impression of the quality of recovery after anesthesia and surgery were rated on postoperative days 1 and 2. These variables were evaluated as follows: vomiting as presence (Y) or absence (N); nausea, dizziness, and headache on a 4-point ordinal scale (0=none, 1=mild, 2=moderate, 3=severe). The IVPCA button-hit counts, fentanyl consumption, and pain rescue (50 mg flurbiprofen), and anti-emetic drug requirements (10 mg metoclopramide) were also recorded.

To evaluate the secondary endpoint of “quality of recovery after anesthesia and surgery”, 2 questionnaires, viz. the QoR-40J and Hospital Anxiety and Depression Scale (HADS), were preoperatively submitted to the enrolled patients. Briefly, the QoR-40J is a Japanese version of a 40-item questionnaire intended to evaluate the quality of recovery after anesthesia and surgery, where each item is scored on a 5-point Likert scale: the global QoR-40J ranges from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery). The items are grouped according to the following subscales (dimensions): 9 items on emotional state, 12 on physical comfort, 7 on patient support, 5 on physical independence, and 7 on pain. The score of the HADS ranged from 0 to 21, and assesses whether the symptoms of anxiety/depression are absent (0–7), possible (8–10), or severe (11–21).

**Anesthetic and Surgical Management**

Standard monitoring was applied to patients upon arrival in the operating room. Anesthesia was induced with propofol (2.0–2.5 mg/kg), rocuronium (0.6 mg/kg), and remifentanil (0.2–0.3 μg · kg⁻¹ · min⁻¹). Anesthesia was maintained with remifentanil, rocuronium (7 μg · kg⁻¹ · min⁻¹), and sevoflurane (1.5%–2.5%), which were titrated to a bispectral index of 40–60 and a mean arterial blood pressure value within 20% of the baseline measures. Ventilation was controlled mechanically using a 45% oxygen-air gas mixture to maintain an end-tidal carbon dioxide concentration of 35–40 mmHg. After tracheal intubation, a gastric tube was inserted via the nose or mouth and removed immediately before or after tracheal extubation. Lactated Ringer’s solution was used for fluid resuscitation at a rate of 6–8 mL/kg. Approximately 30 min before surgery was completed, fentanyl (200 μg) and droperidol (0.5 mg) were injected; then, a disposable IVPCA device was connected to the intravenous line to begin the infusion. Neuromuscular blockade was reversed with (2–4 mg/kg) before tracheal extubation.

The IVPCA was applied during the first 24 h after the completion of surgery. The amount of fentanyl used in this study was determined in reference to previous reports. Fentanyl at either 15 μg/mL (F15 group) or 30 μg/mL (F30 group) was administered into each pump. As mentioned above, the IVPCA device was initially programmed to deliver fentanyl at a basal rate of 1.0 mL/h and a bolus dose of 1.0 mL, with a lockout time of 10 min. Patients were instructed to push the button for IVPCA whenever they felt pain. In both groups, NSAIDs (flurbiprofen, 50 mg) were administered for inadequate pain control, and the use of anti-emetics (metoclopramide, 10 mg) was recorded. After the patients started drinking on postoperative day 1, 200 mg of celecoxib was initially prescribed, followed by a dosage of 100 mg twice daily. Laparoscopic cholecystectomy with a conventional port setting was performed by a surgeon (Y.M.) or by other surgeons under supervision of Y.M.

**Statistical Analysis**

The χ² test and Fisher’s exact test was used to compare the categorical variables. An unpaired t-test and Mann-Whitney test were used to compare the difference in distribution between two groups. Pearson’s correlation test was used to compare the correlation of the two variables. For the prospective study, a power calculation based on VAS scores from a previous study, with a statistical power of 80% and α<0.05, identified that a minimum
Results
Firstly, we sought to overview the usage and feasibility of IVPCA after surgery under general anesthesia. From the review of the medical records that we retrospectively collected (n=288), 18% and 20% of patients that complained of intolerable pain and PONV, respectively, were identified (Table 1). IVPCA was most frequently used for gastrointestinal surgery, including laparoscopic cholecystectomy, in our institute (n=87), where 33% (n=29) of patients complained of intolerable pain, while postoperative pain could be controlled in 67% of patients (Table 1). No patient developed respiratory depression in this cohort. Among patients who were administrated anti-emetic drugs, including droperidol and/or metoclopramide, during surgery, 17% (16/94) patients experienced PONV (Table 2). No significant difference in the incidence of PONV (p=0.83) or cessation of IVPCA was noted among the administered drugs (p=0.53; Table 2).

From the observations mentioned above, we further sought to elucidate the optimal regimen for IVPCA in a prospective study. The demographic data of the patients are shown in Table 3. In this prospective study, 43 patients (F15, n=21; F30, n=22) completed the study protocol. Four patients were excluded from the study because of IVPCA cessation due to severe nausea or vomiting (F15, n=2; F30, n=2). There were no significant differences in baseline variables between the groups (Table 3).

In terms of the VAS score (Table 4), the VAS score with movement was lower in the F30 group than in the F15 group on postoperative day 1, (F15: 52.4±23.7, F30: 38.2±24.0, p<0.05). Although the VAS score analysis showed a tendency for the F30 group to have a lower score in general, there was no significant difference between the groups with respect to other points (Table 4).

Fentanyl use via IVPCA, button-hit counts, and the requirements for NSAIDs and antiemetic drugs are listed in Table 5. Increased fentanyl consumption was observed
Table 4  Visual analogue scale (VAS) scores

|                  | F15 (n=21)* | F30 (n=22)* | p value |
|------------------|-------------|-------------|---------|
| at rest          |             |             |         |
| end of surgery   | 36.4±29.2b  | 37.2±21.6   | 0.91    |
| postoperative day 1 | 42.9±24.2  | 31.1±22.9   | 0.11    |
| postoperative day 2 | 30.0±21.7  | 24.1±21.5   | 0.37    |
| with movement    |             |             |         |
| end of surgery   | 52.6±36.9   | 40.5±24.2   | 0.21    |
| postoperative day 1 | 52.4±23.7  | 38.2±24.0   | 0.05    |
| postoperative day 2 | 37.8±19.8  | 31.3±22.3   | 0.31    |

*F15, fentanyl 15 μg/mL at a basal rate of 1 mL/h and F30, 30 μg/mL at a basal rate of 1 mL/h

Table 5  Postoperative data

|                  | F15 (n=21)c | F30 (n=22)c | p value |
|------------------|-------------|-------------|---------|
| Fentanyl (μg)    | 874.8±156.8 | 1,553.3±208.4 | <0.001 |
| BHC*             | 22±26.9     | 13±13.9     | 0.195   |
| NSAID requirement| 6 (30.0%)   | 6 (27.2%)   | 0.927   |
| Antiemetic require| 6 (30%)   | 3 (14%)     | 0.239   |

*BHC, button hit counts

The HADS and global and dimensional QoR-40J scores (see description in Materials and Methods) are presented in Table 6. The HADS scores and the preoperative global and dimensional QoR-40J scores showed no significant differences between the groups. On postoperative days 1 and 2, however, the dimensional QoR-40J scores of pain subscales were significantly better (higher) in the F30 group than in the F15 group (p=0.021, p=0.024, respectively). However, the scores at the other time points did not differ between the two groups. In addition, there was no statistically significant difference in the incidence of side effects between the two groups (Table 7).

Lastly, we analyzed the correlation among the scores of global and dimensional QoR-40J and VAS at each time point, to study the association of postoperative pain with physical/emotional status. The global QoR-40J (r=0.72, p<0.05), dimensional QoR-40J of subscales of emotional state (r=0.77, p<0.05), and the subscales of pain (r=0.61, p<0.05) scores on postoperative day 1 correlated significantly with those on day 2 (Fig. 1). For other variables, the results (day 1 vs. day 2) were as follows: physical comfort (r=0.43, p=0.08), physical independence (r=0.41, p<0.05), and psychological support (r=0.69, p<0.05).

On postoperative day 1, the VAS scores both at rest and with movement exhibited weak correlations with the HADS scores (at rest: r=0.37, p<0.05; with movement: r=0.35, p<0.05). Other pain scores and side effects did not correlate with the HADS scores (day 2 at rest: r=−0.16, p=0.29; with movement: r=−0.14, p=0.36). Dimensional QoR-40J of subscales of pain correlated with both the subscales of the emotional state (postoperative day 1: r=0.41, p<0.05; day 2: r=0.61, p<0.05) and global QoR-40 scores on both postoperative days (day 1: r=0.71, p<0.05; day 2: r=0.72, p<0.05; Fig. 2).

Discussion

Pain is one of the most common complications associated with patient discomfort during the early postoperative period. Postoperative pain can increase the mortality rate and the risk of adverse effects on multiple organs, complication incidence, and the development of chronic...
pain that affects a patient’s quality of life. In the present study, we demonstrated that pain control after elective laparoscopic cholecystectomy could be better achieved with 30 μg/mL fentanyl via IVPCA than with 15 μg/mL fentanyl IVPCA. In addition, we showed that reduced postoperative pain allowed a better comparison of the patient’s physical and emotional states and could enhance patient satisfaction.

Advances in the laparoscopic cholecystectomy have reduced many complications, including pain. Nonetheless, when compared to open surgery, laparoscopic cholecystectomy sometimes incurs intense pain at an early postoperative stage. In addition, the pattern of pain after laparoscopic cholecystectomy is complex, and patients are unlikely to benefit from similar analgesic treatment of open surgery. Moreover, Bisgaard et al. reported that 60% of patients receiving only periodic oral NSAID treatment claimed to experience a moderate-to-high level of pain and continued to report pain even 1 week postoperatively, supporting the requirement of opioid administration to manage postoperative pain because of individual differences in pain thresholds.

PONV was the most frequent side effect of opioid administration with a reported incidence of 20%–30%; the previously reported incidence was higher than that in our study (18%). This difference was possibly due to dis-

### Table 6  HADS and QoR-40J scores

|                       | HADSa | QoR-40b | p value |
|-----------------------|-------|---------|---------|
| **F15** (n=21)c       | 3.95±3.9 | 4.41±4.1 | 0.712   |
| Emotional state       |       |         |         |
| preoperative          | 42 (23–45) | 42 (32–45) | 0.767   |
| postoperative day 1   | 37 (16–45) | 37 (24–45) | 0.857   |
| postoperative day 2   | 38 (9–45)  | 40 (27–45) | 0.483   |
| Physical comfort      |       |         |         |
| preoperative          | 58 (49–60) | 57 (48–60) | 0.593   |
| postoperative day 1   | 43 (28–58) | 46 (21–59) | 0.843   |
| postoperative day 2   | 52 (32–60) | 52 (37–60) | 0.96    |
| Psychological support |       |         |         |
| preoperative          | 33 (26–35) | 32 (17–35) | 0.661   |
| postoperative day 1   | 29 (15–35) | 30 (16–35) | 0.67    |
| postoperative day 2   | 29 (19–35) | 31 (17–35) | 0.319   |
| Physical independence |       |         |         |
| preoperative          | 24 (23–25) | 24 (15–25) | 0.537   |
| postoperative day 1   | 18 (6–25)  | 18 (6–25)  | 0.962   |
| postoperative day 2   | 22 (13–25) | 21 (5–25)  | 0.596   |
| Pain                  |       |         |         |
| preoperative          | 34 (31–35) | 34 (31–35) | 0.615   |
| postoperative day 1   | 27 (16–30) | 31 (23–35) | 0.021   |
| postoperative day 2   | 29 (16–35) | 32 (24–35) | 0.024   |
| Global QoR-40         |       |         |         |
| preoperative          | 192 (161–200) | 190 (160–200) | 0.794 |
| postoperative day 1   | 160 (107–197) | 162 (112–195) | 0.775 |
| postoperative day 2   | 173 (105–200) | 175 (129–200) | 0.794 |

aHADS, hospital anxiety and depression scale
bQoR-40J, Japanese version of the 40-item quality of recovery scoring system
cF15, fentanyl 15 μg/mL at a basal rate of 1 mL/h and F30, 30 μg/mL at a basal rate of 1 mL/h

### Table 7  Side effects

|               | F15a (n=21) | F30c (n=22) | p value |
|---------------|-------------|-------------|---------|
| vomiting (Y : N) | 6 : 15      | 5 : 17      | 0.652   |
| nausea        | 1.2 (0–3)   | 1.3 (0–3)   | 0.701   |
| headache      | 1.3 (0–3)   | 0.79 (0–3)  | 0.92    |
| dizziness     | 1.9 (0–3)   | 1.9 (0–3)   | 0.988   |

aF15, fentanyl 15 μg/mL at a basal rate of 1 mL/h and F30, 30 μg/mL at a basal rate of 1 mL/h
similarities in the protocol. Using higher doses of opioids may increase the incidence of PONV. Thus, in our prospective study, we used an anti-emetic drug during surgery to prevent PONV. Unexpectedly, the postoperative onset of PONV was 25%, and the actual rate of IVPCA cessation due to the postsurgical use of antiemetic drugs was 8%, as was the IVPCA cessation rate in the retrospective study. Notably, a higher fentanyl concentration did not significantly increase the incidence of PONV, and no significant differences in any side effects were observed between the two groups, or in the retrospective study and the previous study.

It has been reported that the quality of recovery from anesthesia and surgery is one of the factors that is directly associated with patients’ satisfaction. Like- wise, postoperative discomfort and complications could lead to later feeding, ambulation, and a prolonged hospital stay. The QoR-40 is the best instrument for assessing the recovery of patients who have undergone surgery or have undergone anesthesia. Efforts towards precisely measuring and evaluating the QoR-40 could improve the overall quality of recovery and enhance patient satisfaction. In our study, we used the Japanese version of the QoR-40 (QoR-40J), which has been tested for its validity, reliability, and feasibility in clinical evaluations of postoperative recovery. The QoR-40J pain scores on postoperative days 1 and 2 tended to be better in the F30 than in the F15 group. In an investigation of each category on both postoperative days, we found that an improvement in the emotional state category on day 1 was also notable on day 2. The same result was observed for the global QoR-40J. As our treatment schedule included the use of
IVPCA for 24 h after surgery and the internal use of the same NSAIDs in both groups, we concluded that early postoperative pain control influences the patient’s pain for up to 2 days after surgery.

In this study, we have also evaluated the correlation between postoperative VAS and HADS scores. However, we were unable to identify clear correlations between the different methods and patients’ postoperative conditions, indicating that preoperative fear did not have an important influence on postoperative pain relief.

This study has some limitations. This study was conducted to compare different fentanyl doses allocated to the 2 subject groups; therefore, a non-opioid treatment was not evaluated. The inclusion of a non-opioid group may have led to different results regarding pain, side effects, and patient satisfaction. Secondly, we could not evaluate pain conditions at a later time than postoperative day 2. Lastly, this study was conducted using a relatively small number of patients. Consequently, additional well-designed clinical studies with larger sample sizes are warranted to evaluate the efficacy and safety of this mode of analgesia.

Thus, in conclusion, the postoperative pain as well as the physical and emotional quality of recovery in patients who have undergone laparoscopic cholecystectomy can be alleviated by sufficient doses of opioids.

Acknowledgements: We would like to thank our colleagues.
and operating room pharmacists. We would also like to thank Dr. Yuu Tanaka of the Anesthesiology at the Nara Medical University who provided constructive comments and encouragement for the study.

Conflict of Interest: The authors declare no conflict of interest.

References
1. Boddy AP, Mehta S, Rhodes M: The effect of intraperitoneal local anaesthesia in laparoscopic cholecystectomy: a systematic review and meta-analysis. Anesth Analg 2006; 103: 682–688.
2. Ekstein P, Szold A, Sagie B, Werbin N, Klausner JM, Weinbroum AA: Laparoscopic surgery may be associated with severe pain and high analgesia requirements in the immediate postoperative period. Ann Surg 2006; 243: 41–46.
3. Hernández-Palazón J, Tortosa JA, Nuño de la Rosa V, Giménez-Viudes J, Ramírez G, Robles R: Intraperitoneal application of bupivacaine plus morphine for pain relief after laparoscopic cholecystectomy. Eur J Anaesthesiol 2003; 20: 891–896.
4. Abdulla S, Eckhardt R, Netter U, Abdulla W: A randomized, double-blind, controlled trial on non-opioid analgesics and opioid consumption for postoperative pain relief after laparoscopic cholecystectomy. Acta Anaesthesiol Belg 2012; 63: 43–50.
5. Lebovits AH, Zenetos P, O’Neill DK, Cox D, Dubois MY, Jansen LA, Turndorf H: Satisfaction with epidural and intravenous patient-controlled analgesia. Pain Med 2001; 2: 280–286.
6. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA: Regional anesthesia in the anticoagulated patient: Defining the risks (The Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth and Pain Med 2003; 28: 172–197.
7. Johnson A: Laparoscopic surgery. Lancet 1997; 349: 631–635.
8. Murphy GS, Szokol JW, Greenberg SB, Avram MJ, Vender JS, Nisman M, Vaughan J: Preoperative dexamethasone enhances quality of recovery after laparoscopic cholecystec-

tomy: effect on in-hospital and postdischarge recovery outcomes. Anesthesiology 2011; 114: 882–890.
9. Murphy GS, Szokol JW, Greenberg SB, Avram MJ, Vender JS, Nisman M, Vaughan J: Preoperative dexamethasone enhances quality of recovery after laparoscopic cholecystectomy: effect on in-hospital and postdischarge recovery outcomes. Anesthesiology 2011; 114: 882–890.
10. Mouton WG, Bessell JR, Otten KT, Maddern GJ: Pain after laparoscopy. Surg Endosc 1999; 13: 445–448.
11. Bisgaard T, Klasrkov B, Rosenberg J, Kehlet H: Characteristics and prediction of early pain after laparoscopic cholecystectomy. Pain 2001; 90: 261–269.
12. Tanaka Y, Wakaia T, Fukuhara S, Nishiwada M, Inoue S, Kawaguchi M, Furuya H: Validation of the Japanese version of the quality of recovery score QoR-40. J Anesth 2011; 25: 509–515.
13. Zigmund AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.
14. Kim WH, Lee JH, Ko JS, Hahn TS, Lee SM, Cho HS: The effect of patient-controlled intravenous analgesia on postoperative hypokalemia in patients undergoing laparoscopic cholecystectomy. J Anesth 2011; 25: 685–691.
15. Pavlin JD, Kent CD: Recovery after ambulatory anesthesia. Curr Opin Anesthesiol 2008; 21: 729–735.
16. Wiesel S, Grillas R: Patient-controlled analgesia after laparoscopic and open cholecystectomy. Can J Anaesth 1995; 42: 37–40.
17. Madsen MR, Jensen KE: Postoperative pain and nausea after laparoscopic cholecystectomy. Surg Laparosc Endosc 1992; 2: 303–305.
18. Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S: Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003; 97: 62–71.
19. Kehlet H, Jensen TS, Woolf CJ: Persistent postsurgical pain: risk factors and prevention. Lancet 2006; 367: 1618–1625.
20. Brandsborg B: Pain following hysterectomy: epidemiological and clinical aspects. Dan Med J 2012; 59: B4374.

(Received, February 25, 2016)
(Accepted, April 12, 2016)